MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
I-Mab Biopharma Co. (NASDAQ: IMAB)
Organization & Developments: I-Mab
Parents
I-Mab Biopharma Co. (NASDAQ: IMAB)
Children
2020: I-Mab Biopharma_fiercepharma
2025: I-Mab lays off 27% of workforce after pivoting to CLDN18.2 bispecific
I-Mab (NASDAQ: IMAB) is a global biotech company focused on discovering, developing and commercializing novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases.
I-Mab’s business strategy is two-pronged: On the licensing side, it selects differentiated immuno-oncology and autoimmune disease drugs that have shown preliminary efficacy elsewhere. And meanwhile, it's moving its own early internal portfolio through proof of concept
Jumps
Finance & Acquisitions: I-Mab
Key People: I-Mab